Optimizing Bronchodilator Therapy in Emphysema

Evaluation of bronchodilator responses in patients with "irreversible" emphysema.

Given the emerging physiological and clinical rationale for pharmacological lung-volume reduction, assessment of volume responses to bronchodilators is likely to be highly relevant in chronic obstructive pulmonary disease (COPD). The authors examined the magnitude of lung-volume reduction after acute bronchodilator treatment in patients with advanced emphysema. Eighty-four stable patients with ...

Combination bronchodilator therapy in COPD.

Tests of Bronchodilator Therapy

cavities is rarely reported, and”.. . such a communication was demonstrable [only] at necropsy.”1( ’200) A few years ago, we2 reported three cases of pancreaticopleural fistula demonstrated by the early injection of iodized oil (Lipiodol) into the pleural cavity. In an additional case, we have demonstrated a large communication between the pleural cavity and a pancreatic pseudocyst (Fig 1). We ...

Dual bronchodilator therapy: A review

Inhaled bronchodilators with or without inhaled steroids (IGCs) are the mainstay of pharmacological treatment for stable obstructive airway diseases, including beta2agonists and muscarinic antagonists. Long-acting muscarinic antagonist bronchodilators (LAMA) and long-acting β2-agonists (LABA) are the treatment of choice for moderate to severe chronic obstructive pulmonary disease (COPD). Also, ...

Bronchodilator therapy and hyperactivity in preschool children.

The common report of parents of asthmatic children that inhaled/nebulised salbutamol causes overactive behaviour was investigated. Nineteen children were assessed in a standardised setting before and after the administration of nebulised salbutamol and placebo. Neither parental report nor observer ratings suggested any significant increase in the child's level of activity.